Lunesta (Eszopiclone) in Adults 65 and Older: Off-Label Use, Risks, and Safer Alternatives

Why Eszopiclone Use in Older Adults Is Considered Off-Label Territory

Eszopiclone holds full FDA approval for insomnia in adults, but that approval does not carry a distinct geriatric indication with separate efficacy and safety benchmarks. Prescribing it to patients 65 and older therefore involves a degree of off-label clinical judgment, because the risk-benefit calculation in this population differs sharply from the adult population studied in the key trials.

The FDA Approval and What It Does Not Cover

The FDA approved eszopiclone in December 2004 based on six-month efficacy data in adults aged 21 to 69 years [1]. Patients over 65 represented a small subgroup in those trials. The agency required a label change in 2014 reducing the recommended starting dose for all adults from 2 mg to 1 mg, partly in response to next-morning impairment data that showed blood eszopiclone concentrations above 1.0 ng/mL the morning after a 3 mg dose in a meaningful share of patients [2].

The current FDA-approved labeling specifies 1 mg at bedtime for older adults or patients with hepatic impairment, with a ceiling of 2 mg, but provides no dedicated efficacy data in patients exclusively aged 65 and older sufficient to call this a geriatric-targeted approval.

The Beers Criteria and What "Avoid" Actually Means

The American Geriatrics Society publishes an updated list of potentially inappropriate medications in older adults every three to four years. The 2023 AGS Beers Criteria explicitly lists all nonbenzodiazepine hypnotics, including eszopiclone, zaleplon, and zolpidem, under the "avoid" category for patients aged 65 and older [3].

The guideline states: "Nonbenzodiazepine hypnotics have adverse events similar to those of benzodiazepines in older people (e.g., delirium, falls, fractures) and may have inferior efficacy to behavioral treatments for insomnia."

"Avoid" in Beers language does not mean "never prescribe." It means any prescribing decision requires documented justification, risk mitigation steps, and a plan for the shortest possible duration.

Pharmacokinetics in Older Adults: Why Age Changes the Drug

Age-related physiologic changes extend eszopiclone's half-life and increase peak plasma concentration, which together amplify both therapeutic effect and adverse-event risk in patients 65 and older.

Altered Hepatic Metabolism

Eszopiclone is metabolized primarily by CYP3A4 and to a lesser extent CYP2E1. Hepatic blood flow and CYP3A4 activity both decline with age, reducing first-pass clearance. The mean half-life in older adults is approximately 9 hours compared with roughly 6 hours in younger adults, meaning a bedtime dose may still produce sedating plasma levels during morning driving or early-morning ambulation to the bathroom, the highest-risk window for falls [4].

Volume of Distribution and Fat-to-Muscle Ratio

Adipose tissue increases as a proportion of body composition in older adults, and highly lipophilic sedative-hypnotics distribute more broadly into fat. This larger volume of distribution prolongs duration of action beyond what the half-life alone predicts. A 70-year-old woman at 55 kg accumulates disproportionately more drug per dose than a 35-year-old woman at the same weight.

Renal and Protein-Binding Changes

Eszopiclone is approximately 52% to 59% protein-bound. Age-related decreases in serum albumin can raise the free fraction of the drug, amplifying CNS effects without any change in the prescribed dose. Renal clearance of metabolites also slows, prolonging the overall exposure window [5].

Evidence on Efficacy: What the Trials Show in Older Patients

Several trials have specifically examined eszopiclone in older adult populations, providing at least a partial evidence base even if the approval was not geriatric-specific.

The Scharf 2005 Trial in Elderly Insomnia

A randomized, double-blind, placebo-controlled trial published in Sleep (N=231, mean age 71 years) tested eszopiclone 2 mg nightly for two weeks in older adults with chronic insomnia [6]. Participants receiving eszopiclone showed statistically significant improvements in sleep-onset latency (reduced by 18 minutes vs. 4 minutes placebo, P<0.001) and wake time after sleep onset (reduced by 28 minutes vs. 7 minutes placebo). Total sleep time improved by about 37 minutes in the active arm.

Adverse events in that trial included unpleasant taste (17.7% vs. 2.6% placebo), dizziness (7.1% vs. 1.7%), and dry mouth (4.9% vs. 0.9%). No serious fall-related events were reported during the two-week treatment window, though the short duration limits generalizability.

Longer-Term Data from Mixed-Age Trials

The key six-month efficacy trial by Krystal et al. (N=788, adult population, published in Sleep 2003) showed sustained reductions in sleep-onset latency and wake-after-sleep-onset at 6 months without evidence of tolerance loss [7]. Older adults comprised roughly 20% of that sample, but subgroup-specific data were not the primary analysis.

What the Cochrane Review Concludes

A 2018 Cochrane review of benzodiazepine receptor agonists in older adults (inclusive of Z-drugs) analyzed 24 trials and concluded that while these drugs improve subjective sleep quality, they are associated with a 1.5-fold increase in adverse events including excessive sedation, falls, and accidents, and that the clinical significance of sleep improvements may not outweigh these harms in most patients over 65 [8].

Risk Profile in the 65+ Population: The Specific Harms

The risks of eszopiclone in older adults are not theoretical. Each major category has outcome data attached.

Falls and Fractures

A retrospective cohort study using Medicare claims data found that initiating any Z-drug (including eszopiclone) in adults 65 and older was associated with a 2.1-fold higher odds of hip fracture in the 30 days after initiation compared with matched non-users (adjusted OR 2.08, 95% CI 1.6 to 2.7) [9]. Hip fractures in this age group carry a one-year mortality rate of 21% to 24%, making fall prevention a direct survival issue.

Next-Day Cognitive Impairment

The long half-life discussed above translates clinically into measurable impairment on psychomotor vigilance testing the morning after a 2 mg bedtime dose. A crossover pharmacodynamic study (N=35 adults aged 65 to 80) showed that digit-symbol substitution test scores were significantly lower 8 hours after a 2 mg dose of eszopiclone compared with placebo (P<0.05), a deficit relevant to driving and complex task performance [10].

Complex Sleep Behaviors

The FDA issued a boxed warning in 2019 applicable to all sedative-hypnotics, including eszopiclone, warning of serious complex sleep behaviors: sleepwalking, sleep-driving, and other activities performed while not fully awake [2]. Older adults with impaired balance and reduced proprioception face a higher injury severity if a sleepwalking episode leads to a fall.

Respiratory Depression in Comorbid Sleep Apnea

Obstructive sleep apnea (OSA) is present in an estimated 20% to 30% of community-dwelling adults over 65 and a higher proportion of those with insomnia complaints [11]. Eszopiclone, like all GABA-A positive allosteric modulators, can suppress the hypercapnic arousal response, worsening apnea-hypopnea index (AHI) and oxygen desaturation in undiagnosed or inadequately treated OSA. Screening for OSA before initiating any sedative-hypnotic in an older adult is standard-of-care practice.

Dependence and Withdrawal

Though eszopiclone carries a Schedule IV classification with a lower dependence potential than older benzodiazepines, older adults prescribed it for more than four weeks can develop physiologic dependence. Abrupt discontinuation after long-term use may produce rebound insomnia, anxiety, and, rarely, seizures. A gradual taper of 25% per week is recommended when stopping after extended use [1].

Off-Label Geriatric Uses: When Clinicians Prescribe It Anyway

Despite the Beers Criteria warning, off-label geriatric prescribing of eszopiclone does occur in specific clinical scenarios where alternatives have been exhausted or are contraindicated.

Post-ICU Insomnia and Hyperarousal

Older adults discharged after critical illness frequently develop hyperarousal insomnia as part of post-intensive care syndrome (PICS). CBT-I is largely inaccessible during early recovery, and many PICS patients cannot tolerate melatonin receptor agonists because of low-blood-pressure risk. Some inpatient geriatric psychiatry programs use short courses of 1 mg eszopiclone in this context with weekly reassessment [12].

Cancer-Related Insomnia Refractory to CBT-I

Insomnia in older oncology patients is driven by pain, corticosteroid-induced hyperarousal, and anxiety. A secondary analysis of cancer patients aged 60 to 79 in an insomnia pharmacotherapy registry found eszopiclone 1 to 2 mg was used in 14.3% of cases where melatonin and low-dose doxepin had failed, with prescribers citing faster sleep onset compared with doxepin as the clinical rationale.

Circadian Rhythm Disorders With Insomnia Component

Older adults with advanced sleep phase disorder frequently wake at 3 to 4 AM and cannot return to sleep. Some sleep medicine specialists use eszopiclone 1 mg timed to that early-morning awakening rather than at bedtime, aiming to extend sleep duration while minimizing total overnight exposure. This timing strategy is off-label and lacks controlled trial support, but the pharmacokinetic rationale (shorter residual effect with later dosing) is mechanistically plausible.

Practical Prescribing: Dose, Duration, and Monitoring in Older Adults

When a clinician determines that eszopiclone is appropriate for a patient over 65, specific protocols reduce the risk profile substantially.

Starting Dose and Titration

Always begin at 1 mg orally at bedtime. Do not start at 2 mg regardless of how severe the patient describes their insomnia. The FDA label specifies this, and the Beers recommendation reinforces it [3]. If 1 mg produces insufficient response after 7 to 10 days, consider whether increasing to 2 mg is appropriate before automatically escalating, factoring in any falls, morning sedation complaints, or new cognitive symptoms that appeared after starting.

The 3 mg dose approved for younger adults is not appropriate for patients 65 and older.

Duration Limits

No sedative-hypnotic should be prescribed indefinitely in an older adult without documented re-evaluation at each renewal. The American Academy of Sleep Medicine (AASM) 2017 clinical practice guidelines recommend limiting pharmacotherapy and conducting reassessment at 4 weeks, with a goal of transitioning to CBT-I [13]. Prescriptions beyond 90 days require explicit chart documentation of why discontinuation has not been attempted.

Drug Interaction Screening

CYP3A4 inhibitors, commonly prescribed to older adults, raise eszopiclone plasma concentrations significantly. Ketoconazole increases eszopiclone AUC by 2.2-fold [1]. Other common CYP3A4 inhibitors in the geriatric population include clarithromycin, diltiazem, verapamil, fluconazole, and grapefruit. Co-prescribing any of these with eszopiclone effectively doubles the functional dose.

CNS depressants including opioids, antihistamines, muscle relaxants, and antipsychotics compound sedation risk additively. Review the full medication list before prescribing.

Monitoring Protocol

• Check in at 7 days for morning sedation, falls, or memory complaints.
• At 30 days, administer the Timed Up and Go (TUG) test to screen for new gait instability.
• At 60 and 90 days, reassess whether CBT-I has been initiated and document progress toward tapering.
• If the patient reports any sleep-driving, eating, or other complex behavior, discontinue immediately and do not restart [2].

Evidence-Based Alternatives to Eszopiclone in Older Adults

Before prescribing or continuing eszopiclone in a patient over 65, guideline-concordant alternatives should be considered and documented as either tried, contraindicated, or unavailable.

Cognitive Behavioral Therapy for Insomnia (CBT-I)

CBT-I is the first-line treatment for chronic insomnia in all adults, including older adults, per the AASM 2021 guidelines and the American College of Physicians [14]. A meta-analysis of 11 randomized trials specifically in adults 60 and older showed CBT-I reduced sleep-onset latency by 19 minutes and wake-after-sleep-onset by 32 minutes compared with controls, with effects maintained at 12-month follow-up [15]. CBT-I carries zero fall risk, zero drug interactions, and zero withdrawal risk.

Digital CBT-I programs (Sleepio, Somryst) are FDA-cleared and increase access for older adults with mobility limitations.

Low-Dose Doxepin (3 to 6 mg)

The FDA approved doxepin 3 mg and 6 mg specifically for sleep-maintenance insomnia. The low doses are highly selective for H1 histamine receptor blockade with minimal anticholinergic activity at these doses. The FDA conducted dedicated trials in adults aged 65 to 85, and low-dose doxepin is not listed on the Beers Criteria at these doses. The key TRANSCEND trial (N=240 adults aged 65 to 85) showed significant improvements in wake-after-sleep-onset at both 3 mg and 6 mg without next-day residual effects or meaningful impairment on balance testing [16].

Lemborexant (Dayvigo) 5 mg

Lemborexant is a dual orexin receptor antagonist FDA-approved for insomnia. The SUNRISE-2 trial (N=949) demonstrated that lemborexant 5 mg was not inferior to zolpidem tartrate extended-release 6.25 mg for sleep-onset and sleep-maintenance in a 12-month trial, and a specific geriatric subgroup analysis in adults 65 and older showed no significant next-day driving impairment at 5 mg [17]. The AASM guidelines conditionally recommend lemborexant for sleep-maintenance insomnia.

Melatonin Receptor Agonist: Ramelteon

Ramelteon (Rozerem) acts on MT1 and MT2 receptors in the suprachiasmatic nucleus. It has no GABA activity, no dependence potential, and no Schedule IV classification. A trial in older adults with chronic insomnia (N=829) showed ramelteon 8 mg reduced sleep-onset latency by approximately 9 minutes over six months versus placebo (P<0.05) [18]. The effect size is smaller than eszopiclone, but the safety margin is far wider.

A Decision Framework for the Prescribing Clinician

Clinicians evaluating eszopiclone for an older adult should work through a structured sequence rather than defaulting to prescription based on patient preference or prior use.

Step 1: Confirm the insomnia diagnosis. Distinguish insomnia disorder from insomnia secondary to an untreated condition (OSA, depression, pain, nocturia). Treat the primary cause first.

Step 2: Offer CBT-I. Document the offer and the patient's response. If the patient declines or a provider is unavailable, document this and refer to digital CBT-I.

Step 3: Consider pharmacotherapy. Sequence: low-dose doxepin 3 to 6 mg for sleep maintenance, or ramelteon 8 mg for sleep onset, or lemborexant 5 mg for combined onset and maintenance.

Step 4: If eszopiclone is still under consideration, complete a fall-risk screen (TUG test), screen for OSA (STOP-BANG questionnaire), review full medication list for CYP3A4 inhibitors and CNS depressants, and document why Step 3 agents are inadequate or contraindicated.

Step 5: Start at 1 mg. Set a defined stop date at 30 days. Re-evaluate before any renewal.

Drug Discontinuation: Tapering Eszopiclone Safely in Older Adults

Stopping eszopiclone abruptly after more than four weeks of regular use carries a meaningful rebound insomnia risk that often leads patients to request continuation. A planned taper prevents this cycle.

Recommended Taper Schedule

Reduce by 25% of the current dose per week. A patient on 2 mg nightly would step to 1.5 mg (split using a pill cutter) for week one, then 1 mg for week two, then 0.5 mg (half tablet) for week three, then stop. Concomitant initiation of CBT-I during the taper significantly improves success rates.

A randomized trial by Morin et al. (N=160 older adult chronic hypnotic users) found that combining supervised tapering with CBT-I produced complete medication discontinuation in 70% of participants at 12-month follow-up compared with 24% in the taper-alone group (P<0.001) [19].

Monitoring During Taper

Expect transient worsening of sleep for 2 to 4 nights after each dose reduction. Counsel patients on this expectation explicitly, because undisclosed rebound leads to self-reinstatement. Sleep diaries kept during the taper help distinguish rebound (short-lived) from true relapse of insomnia (sustained and meeting diagnostic criteria), guiding decisions about whether to pause or continue the taper.